The role of temozolomide in newly-diagnosed glioblastoma multiforme

M. Jenkinson
DOI: https://doi.org/10.1080/02688690802182314
2008-01-01
British Journal of Neurosurgery
Abstract:Glioblastoma multiforme (GBM) has a poor prognosis despite advances in neurosurgical technique and imaging technology. Adjuvant chemotherapy has been extensively investigated in high-grade glioma with limited success. Stupp et al. investigated the safety and efficacy of concomitant and adjuvant temozolmide (TZM) in newly-diagnosed glioblastoma in a multi-centre study. 573 patients were randomised to either surgery plus radiotherapy alone (XRT), or surgery followed by radiotherapy and TZM, given concomitantly with and after radiotherapy (XRTþTZM). The primary end-point was overall survival (OS); secondary end-points were progression free survival (PFS) and safety. Quality of life was not assessed. The study was powered to detect a 33% increase in median survival. Median follow-up was 28 months, and 480 patients had died. There was a 37% relative reduction in death for patients treated with XRTþTZM compared to XRT alone. Median OS was 14.6 months in the XRTþTZM group compared to 12.1 months in the XRT alone cohort; median survival benefit was 2.5 months. Interestingly the 2-year survival was 26.5% in the group receiving XRTþTZM, compared to 10.4% with XRT alone. Median PFS was also longer in the XRTþTZM group (6.9 months) compared to XRT alone (5.0 months). The complication rate was 7% for serious haematological problems in the XRTþTZM group. Only 47% completed the full 6 cycles of adjuvant TZM. 8% discontinued TZM due to severe toxic effects; the remainder discontinued due to disease progression. There was no evidence of increased incidence of late toxic effects in the XRTþTZM group. This trial demonstrated that TZM administered with and following radiotherapy prolongs survival in glioblastoma. In the companion translational paper to this study, patients noted to respond favourably to TZM were demonstrated to have MGMT (O-methlyguanine-DNA methyltransferase) promoter hypermethylation. The NICE guidelines recommend that temozolomide is a treatment option in patients with GBM and good performance status.
What problem does this paper attempt to address?